Role of Cell-Free Plasma DNA as a Diagnostic Marker for Prostate Cancer

2004 ◽  
Vol 1022 (1) ◽  
pp. 76-80 ◽  
Author(s):  
DARRELL ALLEN ◽  
ASIF BUTT ◽  
DECLAN CAHILL ◽  
MIKE WHEELER ◽  
RICK POPERT ◽  
...  
2008 ◽  
Vol 129 (5) ◽  
pp. 756-762 ◽  
Author(s):  
Annalisa Altimari ◽  
Antonia D’Errico Grigioni ◽  
Elisa Benedettini ◽  
Elena Gabusi ◽  
Riccardo Schiavina ◽  
...  

2021 ◽  
Vol 21 ◽  
Author(s):  
Abdelraouf A. Abonar ◽  
Shymaa E. Ayoub ◽  
Ibrahim A. Tagreda ◽  
Marwa N. Abdelhafez ◽  
Mohammed M Khamiss ◽  
...  

: Increased cell-free DNA (cfDNA) is observed in many diseases such as cancer, myocardial infarction, and autoimmune diseases. It has the ability to alter the receptor cell phenotype, triggering events related to malignant transformation. Our study aims at assessing the use of Cell-free plasma DNA in the diagnosis of metastatic and non-metastatic prostate cancer. The study included 180 subjects who were classified into four groups: Group I (GI) included 50 in perfect health subjects as the control group, Group II (GII) included 40 patients with prostatitis, group III (GIII) included 40 patients with benign prostatic hyperplasia (BPH) and Group IV (GIV) included 50 patients with pre-operative prostate cancer (PC). Evaluation of the plasma level of circulating cell-free DNA by real-time PCR and measurement of total PSA (tPSA) and free to total PSA percent (f/tPSA%) were done for all groups. Our study revealed that the level of tPSA was significantly higher in prostate cancer patients while levels of f/t PSA were found to be significantly lower. The level of cfDNA was significantly higher in prostate cancer patients (399.9±88.6ng/ul) when compared to that of the group I (12.1±1.5ng/ul) (p<0.01), group II (14.7±2.4 ng/ul) (p<0.01), and group III (26.6±45.6 ng/ul) (p<0.01) respectively. There was a statistically significant difference in yields of cfDNA between metastatic and non- metastatic groups (P=0.03) with a higher level in the metastatic group.


2015 ◽  
Vol 41 (1-3) ◽  
pp. 34-40 ◽  
Author(s):  
Anna Clementi ◽  
Grazia Maria Virzì ◽  
Alessandra Brocca ◽  
Silvia Pastori ◽  
Massimo de Cal ◽  
...  

Background: The identification of highly reliable outcome predictors in severe sepsis is important to define disease severity, predict bedside prognosis and monitor response to treatment. Cell-free plasma DNA (cfDNA) has been recently proposed as a possible prognostic marker of clinical outcome in septic patients. In this study, we investigated the prognostic value of cfDNA in patients with sepsis and its possible correlation with caspase-3, IL-6 and IL-18 levels. Methods: We enrolled 34 patients admitted to the intensive care unit (ICU). Out of these 34, 27 patients were septic and 7 were non-septic. cfDNA was extracted from plasma and quantified by real time PCR. Plasma levels of caspase-3, IL-6 and IL-18 were measured by ELISA. Results: We observed significantly higher levels of cfDNA in septic patients. No significant differences were found between cfDNA levels in patients with Gram+, Gram- and fungal infections. Out of the 27 septic patients, 12 developed acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT), and cfDNA levels resulted to be higher in this group. Out of the 27 septic patients, 11 had a negative outcome during the ICU stay. The cfDNA concentrations at admission were higher in non-survivors than in survivors. Caspase-3, IL-6 and IL-18 levels were significantly higher in septic patients when compared to these levels in non-septic patients and correlated with cfDNA levels. Conclusion: cfDNA can be considered a good prognostic marker of clinical outcome in septic patients. Its levels increase in case of AKI complicating sepsis, in particular if CRRT is needed, and are associated with poor outcome. Caspase-3, IL-6 and IL-18 levels are higher in septic patients and correlate to cfDNA concentrations.


2013 ◽  
Vol 6 (1) ◽  
pp. 2 ◽  
Author(s):  
Ricardo Moreno ◽  
Pamela O Delgado ◽  
Patrícia G Coelho ◽  
Sarah R Marsicano ◽  
Viviane AV Boas ◽  
...  

Tumor Biology ◽  
2013 ◽  
Vol 34 (5) ◽  
pp. 2921-2927 ◽  
Author(s):  
Marcelo L. Wroclawski ◽  
Ary Serpa-Neto ◽  
Fernando L. A. Fonseca ◽  
Oseas Castro-Neves-Neto ◽  
Alexandre S. F. L. Pompeo ◽  
...  

2015 ◽  
Vol 35 (7) ◽  
pp. 755-758
Author(s):  
Grazia Maria Virzì ◽  
Sabrina Milan Manani ◽  
Vincenzo Cantaluppi ◽  
Alessandra Brocca ◽  
Massimo de Cal ◽  
...  

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e16058-e16058
Author(s):  
Marcelo L. Wroclawski ◽  
Ary Serpa ◽  
Fernando L. A. Fonseca ◽  
Oseas Castro Neves Neto ◽  
Antônio C. L. Pompeo ◽  
...  

e16058 Background: Cell free plasma DNA (CF–pDNA) may have diagnostic and prognostic value in patients with Prostate Cancer (PCa). Methods: We included 133 men with PCa and 33 controls. PCa patients had blood drawn every 3 months for 2 years. CFpDNA was measured by spectrophotometry. Results: CF-pDNA had an area under the curve of 0.824 with a sensitivity of 66.2%, a specificity of 87.9% ,a positive and negative likelihood ratios of 5.46 and 0.39, respectively. There was no statistical significant correlation between CF-pDNA levels at study entry with PSA, Gleason score, stage and biochemical recurrence free survival(BRFS). However, with a mean follow up of 13.5 months, we observed significantly shorter BRFS for patients with at least one value above 140 ng/ mL of CF-pDNA during follow up (p= 0.048). Conclusions: CF-pDNA is a potentially valuable biomarker for PCa diagnosis and may have a prognostic role during follow-up of patients with PCa.


2004 ◽  
Vol 171 (4S) ◽  
pp. 108-108
Author(s):  
Rainer Kuefer ◽  
Kathleen Day ◽  
Jonathan Rios-Doria ◽  
Matthias Hofer ◽  
Arul Chinnaiyan ◽  
...  

2020 ◽  
Author(s):  
W Kisel ◽  
S Conrad ◽  
S Füssel ◽  
U Sommer ◽  
GB Baretton ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document